Latest Financing News

OM Holdings Limited reported a sharp decline in profit and EBITDA for FY2025, impacted by lower selling prices and market competition, while preparing to complete a major asset disposal valued at US$120 million.

Botanix Pharmaceuticals reports a surge in Sofdra sales driving revenue to $16.5 million, yet the company records a $33.2 million loss amid expanded marketing and operational costs. A $45 million capital raise aims to support growth and supply chain improvements.

Synertec Corporation Limited reported a 20% increase in revenue to $10.2 million for the half-year ended 31 December 2025, alongside a 40% improvement in net loss after tax. The company’s Powerhouse renewable energy system continues to gain traction, supported by strategic partnerships and expanded manufacturing.

Burgundy Diamond Mines reported a net loss of $86.8 million for 2025, reflecting operational challenges including the suspension of Point Lake mining due to adverse tariffs. The company secured $83.4 million in Canadian tariff relief financing to bolster liquidity and restructured its debt amid ongoing market uncertainties.

NoviqTech Limited reported a widening loss of $2.83 million for 2025, alongside a severe drop in cash reserves and a looming going concern uncertainty flagged in its upcoming audit.

Investigator Silver Limited’s Definitive Feasibility Study confirms the Paris Silver Project as a high-margin, low-risk development with rapid payback and modest funding needs. The study outlines a conventional open-pit mine in South Australia, poised for near-term production with robust financial metrics.

Clarity Pharmaceuticals has reported a steep 136% increase in its half-year loss to $55.6 million, alongside the closure of its European subsidiary, signaling a challenging period for the ASX-listed biotech.

Lumos Diagnostics reported a 74% increase in its half-year loss to US$4.88 million, despite strong progress with its FebriDx diagnostic test and a landmark US distribution agreement. The company awaits a critical FDA decision that could unlock significant revenue growth.

Kina Securities Limited reported a 20% increase in statutory net profit after tax to PGK 120.7 million for 2025, driven by strong revenue growth and loan book expansion. The bank declared a higher final dividend and anticipates continued earnings growth in 2026 amid favourable economic conditions and tax cuts.

Bass Oil reported steady January production with a notable regulatory green light for its Vanessa gas field acquisition and a $3.5 million grant to accelerate the Kiwi gas field development.

GLG Corp Ltd reported an 18.7% drop in revenue to USD 54.1 million for the half year ended December 2025, resulting in a net loss amid challenging macroeconomic conditions and tariff pressures. Despite operational efficiencies improving gross margins, the company refrained from declaring an interim dividend.

Anteris Technologies Global Corp. posted a $94.2 million loss for 2025 amid a 29% revenue decline, while progressing its pivotal DurAVR THV clinical trial and securing $320 million in early 2026 financings.